Adjuvant Global Health Technology Fund De, L.p. - Net Worth and Insider Trading
Adjuvant Global Health Technology Fund De, L.p. Net Worth
The estimated net worth of Adjuvant Global Health Technology Fund De, L.p. is at least $44 Million dollars as of 2024-11-05. Adjuvant Global Health Technology Fund De, L.p. is the 10% Owner of Elevance Health Inc and owns about 2,597,380 shares of Elevance Health Inc (ANTX) stock worth over $41 Million. Adjuvant Global Health Technology Fund De, L.p. is also the 10% Owner of AN2 Therapeutics Inc and owns about 2,373,500 shares of AN2 Therapeutics Inc (ANTX) stock worth over $3 Million. Details can be seen in Adjuvant Global Health Technology Fund De, L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Adjuvant Global Health Technology Fund De, L.p. has not made any transactions after 2024-01-16 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Adjuvant Global Health Technology Fund De, L.p.
Adjuvant Global Health Technology Fund De, L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Adjuvant Global Health Technology Fund De, L.p. owns 1 companies in total, including AN2 Therapeutics Inc (ANTX) .
Insider Ownership Summary of Adjuvant Global Health Technology Fund De, L.p.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ANTX | AN2 Therapeutics Inc | 2024-01-16 | 10 percent owner |
Adjuvant Global Health Technology Fund De, L.p. Latest Holdings Summary
Adjuvant Global Health Technology Fund De, L.p. currently owns a total of 2 stocks. Among these stocks, Adjuvant Global Health Technology Fund De, L.p. owns 2,597,380 shares of Elevance Health Inc (ANTX) as of March 29, 2022, with a value of $41 Million and a weighting of 94.08%. Adjuvant Global Health Technology Fund De, L.p. also owns 2,373,500 shares of AN2 Therapeutics Inc (ANTX) as of January 16, 2024, with a value of $3 Million and a weighting of 5.92%.
Latest Holdings of Adjuvant Global Health Technology Fund De, L.p.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ANTX | Elevance Health Inc | 2022-03-29 | 2,597,380 | 15.84 | 41,142,499 |
| ANTX | AN2 Therapeutics Inc | 2024-01-16 | 2,373,500 | 1.09 | 2,587,115 |
Holding Weightings of Adjuvant Global Health Technology Fund De, L.p.
Adjuvant Global Health Technology Fund De, L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Adjuvant Global Health Technology Fund De, L.p. has made a total of 1 transactions in Elevance Health Inc (ANTX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Elevance Health Inc is the acquisition of 166,666 shares on March 29, 2022, which cost Adjuvant Global Health Technology Fund De, L.p. around $2 Million.
According to the SEC Form 4 filings, Adjuvant Global Health Technology Fund De, L.p. has made a total of 8 transactions in AN2 Therapeutics Inc (ANTX) over the past 5 years, including 1 buys and 7 sells. The most-recent trade in AN2 Therapeutics Inc is the sale of 100,000 shares on January 16, 2024, which brought Adjuvant Global Health Technology Fund De, L.p. around $2 Million.
Insider Trading History of Adjuvant Global Health Technology Fund De, L.p.
- 1
Adjuvant Global Health Technology Fund De, L.p. Trading Performance
GuruFocus tracks the stock performance after each of Adjuvant Global Health Technology Fund De, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Adjuvant Global Health Technology Fund De, L.p. is -47.3%. GuruFocus also compares Adjuvant Global Health Technology Fund De, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Adjuvant Global Health Technology Fund De, L.p. within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Adjuvant Global Health Technology Fund De, L.p.'s insider trading performs compared to the benchmark.
Performance of Adjuvant Global Health Technology Fund De, L.p.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 4.13 | | | | | |
| Relative Return to S&P 500(%) | 14.92 | | | | | |
Adjuvant Global Health Technology Fund De, L.p. Ownership Network
Ownership Network List of Adjuvant Global Health Technology Fund De, L.p.
Ownership Network Relation of Adjuvant Global Health Technology Fund De, L.p.
Adjuvant Global Health Technology Fund De, L.p. Owned Company Details
What does AN2 Therapeutics Inc do?
Who are the key executives at AN2 Therapeutics Inc?
Adjuvant Global Health Technology Fund De, L.p. is the 10 percent owner of AN2 Therapeutics Inc. Other key executives at AN2 Therapeutics Inc include 10 percent owner Ra Capital Healthcare Fund Lp , Chief Strategy Officer Kevin Michael Krause , and director & Chief Executive Officer Eric Easom .
AN2 Therapeutics Inc (ANTX) Insider Trades Summary
Over the past 18 months, Adjuvant Global Health Technology Fund De, L.p. made 7 insider transaction in AN2 Therapeutics Inc (ANTX) with a net sale of 223,880. Other recent insider transactions involving AN2 Therapeutics Inc (ANTX) include a net sale of 223,880 shares made by Kabeer Aziz , a net sale of 1,747,316 shares made by Ra Capital Healthcare Fund Lp , and a net sale of 10,000 shares made by Kevin Michael Krause .
In summary, during the past 3 months, insiders sold 3,525,094 shares of AN2 Therapeutics Inc (ANTX) in total and bought 1,500,000 shares, with a net sale of 2,025,094 shares. During the past 18 months, 4,090,725 shares of AN2 Therapeutics Inc (ANTX) were sold and 3,287,778 shares were bought by its insiders, resulting in a net sale of 802,947 shares.
AN2 Therapeutics Inc (ANTX)'s detailed insider trading history can be found in Insider Trading Tracker table.
AN2 Therapeutics Inc Insider Transactions
Adjuvant Global Health Technology Fund De, L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Adjuvant Global Health Technology Fund De, L.p.. You might contact Adjuvant Global Health Technology Fund De, L.p. via mailing address: C/o Adjuvant Capital, L.p., 501 Fifth Avenue, Suite 1404, New York Ny 10017.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
